Genentech Inc. has discovered sulfonimidamide compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, autoimmune disease and cardiovascular, dermatological, respiratory, neurological, gastrointestinal and inflammatory disorders, among others.
Recurium IP Holdings LLC has patented antibody-drug conjugates (ADCs) comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 covalently bound to exatecan through a linker reported to be useful for the treatment of cancer.
When oxygen levels of the intestine increase, the appropriate hypoxic conditions for intestinal microbiota are lost. This state may be caused by immune-mediated malfunction of the intestinal epithelium. By controlling oxygen levels, the imbalance in the intestinal microbiome (dysbiosis) can be reduced.
Akari Therapeutics plc has advanced its preclinical development program for long-acting PAS-nomacopan for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The company has produced new and promising versions and progressed from lab scale to pre-GMP optimization, and is targeting an IND application to the FDA in the first half of next year.
To restore hearing function in patients with hearing loss or deafness, cochlear implantation is seen as the only method that works, but insertion of the electrode array may cause direct mechanical injury to the cochlea, with the subsequent loss attributed to an inflammatory response driven by proinflammatory cytokines, reactive oxygen species and apoptotic signals.
While most preclinical research on pediatric cancer is carried out using adult mouse models, there are significant biological differences between children and adults, including age-related differences in the immune system, metabolism and growth factor signaling. In the current study, investigators from the University of Western Australia and Telethon Kids Institute developed a new mouse model of pediatric medulloblastoma, which is the most common childhood brain cancer.
Coya Therapeutics Inc. has announced expansion of its exclusive worldwide rights for the development and commercialization of COYA-301, the company's low-dose IL-2 subcutaneous administration product candidate. COYA-301 is intended to enhance regulatory T-cell (Treg) function in vivo to treat the systemic neuro-inflammation underlying certain autoimmune and neurodegenerative diseases.
Calibr at Scripps Research and the Bill & Melinda Gates Medical Research Institute (Gates MRI) have entered into a strategic licensing agreement to advance development of a novel investigational compound for treatment of tuberculosis (TB).
Researchers from Basking Biosciences Inc. presented preclinical data for BB-031, a novel RNA aptamer that binds and inhibits Von Willebrand Factor (VWF). BB-031 (0.5, 1.0 and 5.0 mg/kg) or placebo were administered to a canine model of large vessel occlusion (LVO) stroke at 6 hours post-LVO with an autologous clot.
RSS
